Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci 1980; 77:7415-7419.

2. Gessain A, Vernant J, Maurs L, Barin F, Gout O, Calender A. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 326:407-410.

3. Osame M. HTLV-I-associated myelopathy; A new clinical entity. Lancet 1986; 1031-2.

4. Cartier LM, Cea JG, Vergara C, Araya F, Born P. Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-I: an axomyelinic degeneration of the central nervous system. J Neuropathol ExpNeurol 1997; 56:403-413.

5. Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y,

et al.

The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J. Acquir Immune Defic syndr 1990; 3:1096.

6. Vine AM, Heaps AG, Kaftantzi L, Mosley A, Asquith B, Witkover A,

et al

. The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol 2004; 173:5121-5129.

7. Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SAR, Mashkani B, Hedayati-Moghaddam MR,

et al

. Human T-lymphotropic virus type 1 prevalence in Northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Rretroviruses 2012.

8. Bangham CRM, Osame M. Cellular immune response to HTLV-I. Oncogene 2005; 24:6035-6046.

9. Rafatpanah H, Pravica V, Farid Hosseini R, Tabatabaei A, Ollier W, Poulton K,

et al.

Association between HLA-DRB1* 01 and HLA-Cw* 08 and outcome following HTLV-I infection. Iran J Immunol 2007; 4:94-100.

10. Jeffery KJM, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD,

et al.

The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000; 165:7278-7284.

11. Kubota R, Hanada K, Furukawa Y, Arimura K, Osame M, Gojobori T,

et al. Genetic stability of human T lymphotropic virus type I despite antiviral pressures by CTLs. J Immunol

2007; 178:5966-5972.

12. Jeffery KJM, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J,

et al.

HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci 1999; 96:3848-3853.

13. Kubota R, Takenouchi N, Matsuzaki T, Takashima H, Izumo S. HLA-A24-restricted HTLV-I-specific CTL response reduces the HTLV-I proviral load but the HLA increases the risk of HAM/TSP. Retrovirol 2011; 8:A113.

14. Osame M, Blattner WA, editors. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP1990: Retrovirol.

15. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L,

et al.

The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-I-associated myelopathy in northeast of Iran. J Neuroimmunol 2012.

16. Zetterquist H, Olerup O. Identification of the< i> HLA-DRB1

∗ 04,- DRB1∗ 07, and< i>-DRB1∗

09 Alleles by PCR Amplification with sequence-specific primers (PCR-SSP) in 2 hr. Hum Immunol 1992; 34:64-74.

17. Allison A, editor. Polymorphism and natural selection in human populations. Cold Spring Harbor symposia on quantitative biology. Cold Spring Harb Lab Press; 1964.

18. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database. Tissue antigens [serial online] 2003; 61:403- 407.Available at: http://www. allelefrequencies. net.

19. Gastaldello R, Iñiguez AM, Otsuki K, Lamas G, Balangero M, Barbas MG

, et al.

HTLV type 1 genetic types among native descendants in Argentina. AIDS Rres Hum Retrov 2008; 24:1139-1146.